首页 > 最新文献

AJO International最新文献

英文 中文
Socioeconomic status and risk of cardiovascular diseases in patients with retinal vein occlusion: A Danish nationwide cohort study 视网膜静脉闭塞患者的社会经济状况与心血管疾病风险:一项丹麦全国性队列研究
Pub Date : 2024-06-22 DOI: 10.1016/j.ajoint.2024.100044
Marie Ørskov , Lasse Jørgensen Cehofski , Torben Bjerregaard Larsen , Toke Bek , Flemming Skjøth , Henrik Vorum

Purpose

This study examines the association between socioeconomic status and the occurrence of both cardiovascular diseases and mortality following retinal vein occlusion (RVO), a condition known to elevate the risk of cardiovascular health issues. Despite recognition of the impact socioeconomic factors might have on a patient's course through the healthcare system, its association with cardiovascular outcomes post-RVO has not previously been thoroughly explored.

Design

Nationwide cohort study.

Methods

We included all subjects with RVO from the Danish nationwide registries diagnosed between 2000 and 2018. Information was combined using a personal identification number each Danish resident is given at birth or upon immigration. We categorized participants by their socioeconomic levels to evaluate the five-year incidence rate of cardiovascular conditions and overall mortality. The analysis was further refined by sex and age groups to elucidate any differential impacts. Furthermore, the cumulative incidence was estimated using the Aalen-Johansen estimator and the differences between the socioeconomic groups were quantified using a cox proportional hazard model. Key quantitative results were summarized, including hazard rate ratios (HR), confidence intervals (CI), and p-values

Results

The cohort was comprised of 14,041 individuals with RVO. Our analysis revealed a relationship between educational attainment and cardiovascular health outcomes. Lower education levels were consistently linked with heightened risks of mortality, diabetes, ischemic heart disease, myocardial infarction, and peripheral artery disease following RVO. Individuals with a middle educational level also exhibited a higher prevalence of peripheral artery disease when compared to those with the highest education levels. In terms of income, the lowest earners faced increased risks across several categories, including mortality, diabetes, heart failure, ischemic heart disease, myocardial infarction, and peripheral artery disease, when compared to the highest-income earners. The middle-income group also showed elevated risks for mortality, heart failure, and peripheral artery disease. Being unmarried was additionally associated with higher risks of mortality and heart failure compared to being married.

Conclusion

Socioeconomic status was significantly associated with clinically relevant differences in post-RVO risk of cardiovascular diseases and death. Our data suggests that socioeconomic factors should be considered in the attempt to reduce the risk of cardiovascular disease and death in patients with RVO.

目的 本研究探讨了社会经济状况与视网膜静脉阻塞(RVO)后心血管疾病发生率和死亡率之间的关系,众所周知,视网膜静脉阻塞会增加心血管健康问题的风险。尽管人们认识到社会经济因素可能会影响患者在医疗保健系统中的治疗过程,但此前尚未深入探讨过社会经济因素与视网膜静脉阻塞后心血管疾病结果之间的关系。我们使用每个丹麦居民在出生时或移民时获得的个人身份号码对信息进行了整合。我们按照社会经济水平对参与者进行分类,以评估心血管疾病的五年发病率和总死亡率。我们还按性别和年龄组进一步细化了分析,以阐明任何不同的影响。此外,还使用 Aalen-Johansen 估算器估算了累积发病率,并使用 cox 比例危险模型量化了社会经济群体之间的差异。结果队列由 14,041 名 RVO 患者组成。我们的分析揭示了教育程度与心血管健康结果之间的关系。受教育程度较低的人患 RVO 后死亡、糖尿病、缺血性心脏病、心肌梗塞和外周动脉疾病的风险一直较高。与受教育程度最高的人相比,受教育程度中等的人患外周动脉疾病的几率也更高。就收入而言,与收入最高的人群相比,收入最低的人群在死亡率、糖尿病、心力衰竭、缺血性心脏病、心肌梗死和外周动脉疾病等几方面面临的风险都有所增加。中等收入人群的死亡率、心力衰竭和外周动脉疾病风险也有所上升。结论:社会经济地位与 RVO 术后心血管疾病和死亡风险的临床相关性差异显著相关。我们的数据表明,在试图降低 RVO 患者罹患心血管疾病和死亡的风险时,应考虑社会经济因素。
{"title":"Socioeconomic status and risk of cardiovascular diseases in patients with retinal vein occlusion: A Danish nationwide cohort study","authors":"Marie Ørskov ,&nbsp;Lasse Jørgensen Cehofski ,&nbsp;Torben Bjerregaard Larsen ,&nbsp;Toke Bek ,&nbsp;Flemming Skjøth ,&nbsp;Henrik Vorum","doi":"10.1016/j.ajoint.2024.100044","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100044","url":null,"abstract":"<div><h3>Purpose</h3><p>This study examines the association between socioeconomic status and the occurrence of both cardiovascular diseases and mortality following retinal vein occlusion (RVO), a condition known to elevate the risk of cardiovascular health issues. Despite recognition of the impact socioeconomic factors might have on a patient's course through the healthcare system, its association with cardiovascular outcomes post-RVO has not previously been thoroughly explored.</p></div><div><h3>Design</h3><p>Nationwide cohort study.</p></div><div><h3>Methods</h3><p>We included all subjects with RVO from the Danish nationwide registries diagnosed between 2000 and 2018. Information was combined using a personal identification number each Danish resident is given at birth or upon immigration. We categorized participants by their socioeconomic levels to evaluate the five-year incidence rate of cardiovascular conditions and overall mortality. The analysis was further refined by sex and age groups to elucidate any differential impacts. Furthermore, the cumulative incidence was estimated using the Aalen-Johansen estimator and the differences between the socioeconomic groups were quantified using a cox proportional hazard model. Key quantitative results were summarized, including hazard rate ratios (HR), confidence intervals (CI), and p-values</p></div><div><h3>Results</h3><p>The cohort was comprised of 14,041 individuals with RVO. Our analysis revealed a relationship between educational attainment and cardiovascular health outcomes. Lower education levels were consistently linked with heightened risks of mortality, diabetes, ischemic heart disease, myocardial infarction, and peripheral artery disease following RVO. Individuals with a middle educational level also exhibited a higher prevalence of peripheral artery disease when compared to those with the highest education levels. In terms of income, the lowest earners faced increased risks across several categories, including mortality, diabetes, heart failure, ischemic heart disease, myocardial infarction, and peripheral artery disease, when compared to the highest-income earners. The middle-income group also showed elevated risks for mortality, heart failure, and peripheral artery disease. Being unmarried was additionally associated with higher risks of mortality and heart failure compared to being married.</p></div><div><h3>Conclusion</h3><p>Socioeconomic status was significantly associated with clinically relevant differences in post-RVO risk of cardiovascular diseases and death. Our data suggests that socioeconomic factors should be considered in the attempt to reduce the risk of cardiovascular disease and death in patients with RVO.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000443/pdfft?md5=8e9df1e4d8e67d78f997a8dabefcee51&pid=1-s2.0-S2950253524000443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-dose atropine for high myopia: An observational cohort study 小剂量阿托品治疗高度近视:一项观察性队列研究
Pub Date : 2024-06-21 DOI: 10.1016/j.ajoint.2024.100046
Anna Mueller , Roberto Warman

Purpose

To describe and compare the spherical equivalent progression of pediatric patients with high myopia undergoing treatment with 0.01 % atropine and those not receiving any myopia therapy.

Design

Retrospective, descriptive cohort study

Methods

In this IRB-approved study, we analyzed the spherical equivalent (SE) progression in children 6–13 years old treated with 0.01 % atropine and those who were not treated for myopia, initial SE of ≤-6 D, astigmatism of ≤2 D, no syndromic conditions, and records of cycloplegic refraction measurements without missing more than one year.

Results

Seventy-five eyes were included, with 87 % belonging to Hispanic patients. The baseline SE (D) was -7.66 ± 1.40 in the atropine group and -7.90 ± 1.38 in the control group. Over three years, atropine-treated eyes demonstrated slower SE progression compared to controls (P = 0.002). Analysis of yearly progression rates (D/year) revealed notably slower progression in the atropine group during the second (P = 0.04) and third (P = 0.02) years.

Conclusion

Our findings suggest that low-dose atropine may be beneficial as a first-line treatment for high myopia due to its favorable safety profile and potential efficacy. Due to limited statistical power, findings should be interpreted cautiously.

目的描述并比较接受 0.01 % 阿托品治疗和未接受任何近视治疗的儿童高度近视患者的球面等效度数进展情况。结果共纳入 75 只眼睛,其中 87% 属于西班牙裔患者。阿托品组的基线 SE (D) 为 -7.66 ± 1.40,对照组为 -7.90 ± 1.38。与对照组相比,经过阿托品治疗的眼睛在三年内的SE进展较慢(P = 0.002)。我们的研究结果表明,小剂量阿托品具有良好的安全性和潜在疗效,可作为高度近视的一线治疗手段。由于统计能力有限,应谨慎解释研究结果。
{"title":"Low-dose atropine for high myopia: An observational cohort study","authors":"Anna Mueller ,&nbsp;Roberto Warman","doi":"10.1016/j.ajoint.2024.100046","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100046","url":null,"abstract":"<div><h3>Purpose</h3><p>To describe and compare the spherical equivalent progression of pediatric patients with high myopia undergoing treatment with 0.01 % atropine and those not receiving any myopia therapy.</p></div><div><h3>Design</h3><p>Retrospective, descriptive cohort study</p></div><div><h3>Methods</h3><p>In this IRB-approved study, we analyzed the spherical equivalent (SE) progression in children 6–13 years old treated with 0.01 % atropine and those who were not treated for myopia, initial SE of ≤-6 D, astigmatism of ≤2 D, no syndromic conditions, and records of cycloplegic refraction measurements without missing more than one year.</p></div><div><h3>Results</h3><p>Seventy-five eyes were included, with 87 % belonging to Hispanic patients. The baseline SE (D) was -7.66 ± 1.40 in the atropine group and -7.90 ± 1.38 in the control group. Over three years, atropine-treated eyes demonstrated slower SE progression compared to controls (<em>P</em> = 0.002). Analysis of yearly progression rates (D/year) revealed notably slower progression in the atropine group during the second (<em>P</em> = 0.04) and third (<em>P</em> = 0.02) years.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that low-dose atropine may be beneficial as a first-line treatment for high myopia due to its favorable safety profile and potential efficacy. Due to limited statistical power, findings should be interpreted cautiously.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000467/pdfft?md5=5f7709c3e439015737541be0912f71f0&pid=1-s2.0-S2950253524000467-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The refractive impact of subretinal fluid in neovascular age-related macular degeneration 新生血管性老年黄斑变性中视网膜下积液对屈光的影响
Pub Date : 2024-06-20 DOI: 10.1016/j.ajoint.2024.100042
Marianne Guldager Schou , Benjamin Sommer Thinggaard , Javad Nouri Hajari , Oliver Niels Klefter , Jakob Grauslund , Yousif Subhi
{"title":"The refractive impact of subretinal fluid in neovascular age-related macular degeneration","authors":"Marianne Guldager Schou ,&nbsp;Benjamin Sommer Thinggaard ,&nbsp;Javad Nouri Hajari ,&nbsp;Oliver Niels Klefter ,&nbsp;Jakob Grauslund ,&nbsp;Yousif Subhi","doi":"10.1016/j.ajoint.2024.100042","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100042","url":null,"abstract":"","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295025352400042X/pdfft?md5=0d1a9f3c43772062ff69fb8a3b1b4057&pid=1-s2.0-S295025352400042X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hidden in plain sight: AI-driven steganography and watermarking for secure transmission of ophthalmic data 隐藏在众目睽睽之下:人工智能驱动的隐写术和水印技术实现眼科数据的安全传输
Pub Date : 2024-06-17 DOI: 10.1016/j.ajoint.2024.100043
Michael Balas , Chris Rudnisky , Edsel B. Ing

Purpose

To explore the application of artificial intelligence (AI) in enhancing steganographic and watermarking techniques for the secure transmission of ophthalmic data. This study aims to delineate the integration of these methods into healthcare frameworks to ensure data confidentiality, integrity, and compliance with regulatory standards.

Design and methods

A descriptive and analytical approach was employed to examine the potential of steganographic and watermarking techniques in ophthalmic data security. The study reviews historical and contemporary uses of these methods and introduces AI as a means to enhance their efficacy and application in medical data transmission. We applied an example use-case of an open-source steganography application that performs both data concealment and watermarking to demonstrate practical implementation.

Results

AI-enhanced steganography allows for the imperceptible embedding of sensitive patient data within digital ophthalmic images, which can significantly obscure the presence of transmitted data from unauthorized parties. Similarly, AI-driven watermarking can embed digital signatures to authenticate image origins and signal alterations, aiding in forensic integrity and compliance verification.

Conclusion

Integrating AI with steganography and watermarking offers promising enhancements to the security and efficiency of ophthalmic data transmission. While these AI-driven techniques contribute to a more robust data-handling framework, their successful deployment requires interdisciplinary collaboration and continuous refinement to address emerging technical and ethical challenges effectively.

目的探索人工智能(AI)在加强眼科数据安全传输的隐写术和水印技术中的应用。设计和方法采用描述性和分析性的方法来研究隐写术和水印技术在眼科数据安全方面的潜力。该研究回顾了这些方法的历史和当代使用情况,并引入人工智能作为提高其功效和在医疗数据传输中的应用的一种手段。我们应用了一个开源隐写术应用程序的用例,该应用程序可同时进行数据隐藏和水印处理,以展示实际应用情况。结果 人工智能增强的隐写术可将敏感的患者数据以不易察觉的方式嵌入数字眼科图像中,这可大大掩盖传输数据的存在,使未经授权的各方无法察觉。同样,人工智能驱动的水印技术可以嵌入数字签名,以验证图像来源和信号更改,从而帮助进行完整性取证和合规性验证。 结论将人工智能与隐写术和水印技术相结合,有望提高眼科数据传输的安全性和效率。虽然这些人工智能驱动的技术有助于建立一个更强大的数据处理框架,但它们的成功部署需要跨学科合作和不断改进,以有效解决新出现的技术和道德挑战。
{"title":"Hidden in plain sight: AI-driven steganography and watermarking for secure transmission of ophthalmic data","authors":"Michael Balas ,&nbsp;Chris Rudnisky ,&nbsp;Edsel B. Ing","doi":"10.1016/j.ajoint.2024.100043","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100043","url":null,"abstract":"<div><h3>Purpose</h3><p>To explore the application of artificial intelligence (AI) in enhancing steganographic and watermarking techniques for the secure transmission of ophthalmic data. This study aims to delineate the integration of these methods into healthcare frameworks to ensure data confidentiality, integrity, and compliance with regulatory standards.</p></div><div><h3>Design and methods</h3><p>A descriptive and analytical approach was employed to examine the potential of steganographic and watermarking techniques in ophthalmic data security. The study reviews historical and contemporary uses of these methods and introduces AI as a means to enhance their efficacy and application in medical data transmission. We applied an example use-case of an open-source steganography application that performs both data concealment and watermarking to demonstrate practical implementation.</p></div><div><h3>Results</h3><p>AI-enhanced steganography allows for the imperceptible embedding of sensitive patient data within digital ophthalmic images, which can significantly obscure the presence of transmitted data from unauthorized parties. Similarly, AI-driven watermarking can embed digital signatures to authenticate image origins and signal alterations, aiding in forensic integrity and compliance verification.</p></div><div><h3>Conclusion</h3><p>Integrating AI with steganography and watermarking offers promising enhancements to the security and efficiency of ophthalmic data transmission. While these AI-driven techniques contribute to a more robust data-handling framework, their successful deployment requires interdisciplinary collaboration and continuous refinement to address emerging technical and ethical challenges effectively.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000431/pdfft?md5=4b01ebaf5cf510377133513973cea0b0&pid=1-s2.0-S2950253524000431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141438705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the ocular trauma score and identification of additional prognostic factors in open-globe injuries 验证眼外伤评分并确定开球损伤的其他预后因素
Pub Date : 2024-06-17 DOI: 10.1016/j.ajoint.2024.100041
Jacob A. Mascaro , Hongyi Ren , Sergei V. Dmitruk , Andrew D. Fernandez , Harrison L. Ngo , Yasaman Ataei , John Le , Surbhi Bansal

Objective

This study's aim was to validate the Ocular Trauma Score (OTS) for open globe injuries and to identify additional pre-operative factors that may affect the final visual acuity outcomes of patients with open globe injuries.

Design

This was a retrospective cross-sectional study done via chart review.

Methods

This was a single center study of patients who presented to VCU Medical Center from 2013 to 2020. A total of 140 patients with open globe injuries were included in the study. OTS was calculated for each patient based on the initial study by Kuhn et al. OTS predicted visual acuities were compared with the actual final visual acuities using Mann Whitney U test. The distribution of visual acuities in each OTS category was also compared with the original study by Kuhn et al. using Chi square analysis. The effects of lens involvement, presence of an intraocular foreign body, zone of injury, and time of surgery on the final visual acuity outcomes were also analyzed using Mann Whitney U test. The main outcome measure was the final visual acuity in Snellen and LogMAR equivalents.

Results

LP/HM was the most common presenting visual acuity category (59%) and OTS 1 was the most common OTS (45%). OTS reliably predicted final visual acuity in most cases, except for OTS 1 and 4, where there were significant differences between our study and the Kuhn et al. study. Of the four pre-operative factors analyzed, lens status and foreign body had significant effects on final visual acuity outcomes – injuries with an atraumatic lens or without an IOFB had better final VAs than predicted by OTS. Zone of injury and time of surgery had no significant effects.

Conclusion

Our study finds that OTS is overall a reliable predictor of final visual acuity and further validates it as a tool for open globe injury prognostication. However, our investigation showed that certain factors were not adequately accounted for by OTS, demonstrating the importance of considering other pre-operative factors when using OTS.

本研究旨在验证眼球开放性损伤的眼外伤评分(OTS),并确定可能影响眼球开放性损伤患者最终视力结果的其他术前因素。研究共纳入了140名开球伤患者。根据Kuhn等人的初步研究计算出每位患者的OTS。采用曼-惠特尼U检验比较OTS预测视力和实际最终视力。此外,还使用奇平方分析法将每个 OTS 类别的视力分布与 Kuhn 等人的原始研究进行了比较。此外,还使用曼-惠特尼 U 检验分析了晶状体受累、是否存在眼内异物、损伤区域和手术时间对最终视力结果的影响。结果LP/HM是最常见的视力类别(59%),OTS 1是最常见的OTS(45%)。在大多数病例中,OTS 能可靠地预测最终视力,但 OTS 1 和 4 除外,我们的研究与 Kuhn 等人的研究存在显著差异。在分析的四个术前因素中,晶状体状态和异物对最终视力结果有显著影响--无创伤晶状体或无IOFB的伤者最终视力比OTS预测的要好。结论:我们的研究发现,OTS总体上是预测最终视力的可靠指标,并进一步验证了其作为开球损伤预后工具的有效性。然而,我们的调查显示,OTS并不能充分考虑某些因素,这表明在使用OTS时考虑其他术前因素非常重要。
{"title":"Validation of the ocular trauma score and identification of additional prognostic factors in open-globe injuries","authors":"Jacob A. Mascaro ,&nbsp;Hongyi Ren ,&nbsp;Sergei V. Dmitruk ,&nbsp;Andrew D. Fernandez ,&nbsp;Harrison L. Ngo ,&nbsp;Yasaman Ataei ,&nbsp;John Le ,&nbsp;Surbhi Bansal","doi":"10.1016/j.ajoint.2024.100041","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100041","url":null,"abstract":"<div><h3>Objective</h3><p>This study's aim was to validate the Ocular Trauma Score (OTS) for open globe injuries and to identify additional pre-operative factors that may affect the final visual acuity outcomes of patients with open globe injuries.</p></div><div><h3>Design</h3><p>This was a retrospective cross-sectional study done via chart review.</p></div><div><h3>Methods</h3><p>This was a single center study of patients who presented to VCU Medical Center from 2013 to 2020. A total of 140 patients with open globe injuries were included in the study. OTS was calculated for each patient based on the initial study by Kuhn et al. OTS predicted visual acuities were compared with the actual final visual acuities using Mann Whitney U test. The distribution of visual acuities in each OTS category was also compared with the original study by Kuhn et al. using Chi square analysis. The effects of lens involvement, presence of an intraocular foreign body, zone of injury, and time of surgery on the final visual acuity outcomes were also analyzed using Mann Whitney U test. The main outcome measure was the final visual acuity in Snellen and LogMAR equivalents.</p></div><div><h3>Results</h3><p>LP/HM was the most common presenting visual acuity category (59%) and OTS 1 was the most common OTS (45%). OTS reliably predicted final visual acuity in most cases, except for OTS 1 and 4, where there were significant differences between our study and the Kuhn et al. study. Of the four pre-operative factors analyzed, lens status and foreign body had significant effects on final visual acuity outcomes – injuries with an atraumatic lens or without an IOFB had better final VAs than predicted by OTS. Zone of injury and time of surgery had no significant effects.</p></div><div><h3>Conclusion</h3><p>Our study finds that OTS is overall a reliable predictor of final visual acuity and further validates it as a tool for open globe injury prognostication. However, our investigation showed that certain factors were not adequately accounted for by OTS, demonstrating the importance of considering other pre-operative factors when using OTS.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000418/pdfft?md5=6e5aa169d839503d20b463201ad0679d&pid=1-s2.0-S2950253524000418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Gabapentinoids in pain resolution after Photorefractive Keratectomy: A Systematic Review and Meta-Analysis 加巴喷丁类药物对缓解光屈光性角膜切割术后疼痛的疗效:系统回顾与元分析
Pub Date : 2024-06-14 DOI: 10.1016/j.ajoint.2024.100039
Obaid Ur Rehman , Eeman Ahmad , Shahzaib Ahmed , Umar Akram , Eeshal Fatima , Aymen Shafqat , Zain Ali Nadeem , Abdullah Ahmed , Imtanan Fazal , Abdulqadir J Nashwan

Introduction

Photorefractive Keratectomy (PRK) is a procedure used for the correction of refractive errors. It is specifically preferred in cases of reduced corneal thickness or anterior basement membrane dystrophy. Despite being a viable treatment option, post-operative pain is one of the main concerns of PRK. Studies have shown that gabapentin and pregabalin reduce pain as compared to placebo after PRK. Therefore, we aim to conduct a meta-analysis that studies the efficacy of gabapentinoids after PRK.

Methods

A comprehensive search was done using PubMed/MEDLINE, Scopus, and the Cochrane Library from inception till March 2024 for published randomized controlled trials (RCTs) that included 18 years or older patients of PRK who used gabapentinoids (Pregabalin, Gabapentin) for pain resolution. RevMan (version 5.3) was used to calculate Mean differences (MD) with their 95 % confidence intervals (CI).

Results

A total of 3 RCTs were included after a comprehensive screening. The studies included 312 participants. The mean age of the participants in the intervention group was 27.3 years. Gabapentinoid therapy was associated with no significant improvement in pain reduction on operation day post-PRK (MD = -0.64; 95 % CI, -1.63 to 0.35; p-value = 0.20) or after 24 h of operation (MD = -0.45; 95 % CI, -2.01 to 1.11; p-value = 0.57). No significant benefit in terms of total rescue analgesia use post-PRK was observed (MD = -0.69; 95 % CI, -2.88 to 1.51; p-value = 0.5). However, a statistically significant benefit was observed two days after PRK (MD = -0.66 (95 % CI, -1.27 to -0.05; p-value = 0.03).

Conclusion

Gabapentinoids do not show significant efficacy in pain resolution post-PRK as compared to the placebo.

导读:光屈光性角膜移植术(PRK)是一种用于矫正屈光不正的手术。它特别适用于角膜厚度减少或前基底膜营养不良的病例。尽管 PRK 是一种可行的治疗方法,但术后疼痛是 PRK 的主要问题之一。研究表明,与安慰剂相比,加巴喷丁和普瑞巴林能减轻 PRK 术后疼痛。从开始到 2024 年 3 月,我们使用 PubMed/MEDLINE、Scopus 和 Cochrane 图书馆对已发表的随机对照试验(RCT)进行了全面检索,这些试验纳入了使用加巴喷丁(普瑞巴林、加巴喷丁)缓解疼痛的 18 岁或以上 PRK 患者。RevMan(5.3 版)用于计算平均差 (MD) 及其 95 % 置信区间 (CI)。这些研究共纳入 312 名参与者。干预组参与者的平均年龄为 27.3 岁。加巴喷丁诺类药物治疗对PRK术后当天(MD = -0.64; 95 % CI, -1.63 to 0.35; p值 = 0.20)或术后24小时后(MD = -0.45; 95 % CI, -2.01 to 1.11; p值 = 0.57)的疼痛缓解无明显改善。PRK术后总的抢救性镇痛使用量没有观察到明显的获益(MD = -0.69;95 % CI,-2.88 至 1.51;p 值 = 0.5)。结论与安慰剂相比,加巴喷丁类药物对缓解 PRK 术后疼痛没有明显疗效。
{"title":"Efficacy of Gabapentinoids in pain resolution after Photorefractive Keratectomy: A Systematic Review and Meta-Analysis","authors":"Obaid Ur Rehman ,&nbsp;Eeman Ahmad ,&nbsp;Shahzaib Ahmed ,&nbsp;Umar Akram ,&nbsp;Eeshal Fatima ,&nbsp;Aymen Shafqat ,&nbsp;Zain Ali Nadeem ,&nbsp;Abdullah Ahmed ,&nbsp;Imtanan Fazal ,&nbsp;Abdulqadir J Nashwan","doi":"10.1016/j.ajoint.2024.100039","DOIUrl":"10.1016/j.ajoint.2024.100039","url":null,"abstract":"<div><h3>Introduction</h3><p>Photorefractive Keratectomy (PRK) is a procedure used for the correction of refractive errors. It is specifically preferred in cases of reduced corneal thickness or anterior basement membrane dystrophy. Despite being a viable treatment option, post-operative pain is one of the main concerns of PRK. Studies have shown that gabapentin and pregabalin reduce pain as compared to placebo after PRK. Therefore, we aim to conduct a meta-analysis that studies the efficacy of gabapentinoids after PRK.</p></div><div><h3>Methods</h3><p>A comprehensive search was done using PubMed/MEDLINE, Scopus, and the Cochrane Library from inception till March 2024 for published randomized controlled trials (RCTs) that included 18 years or older patients of PRK who used gabapentinoids (Pregabalin, Gabapentin) for pain resolution. RevMan (version 5.3) was used to calculate Mean differences (MD) with their 95 % confidence intervals (CI).</p></div><div><h3>Results</h3><p>A total of 3 RCTs were included after a comprehensive screening. The studies included 312 participants. The mean age of the participants in the intervention group was 27.3 years. Gabapentinoid therapy was associated with no significant improvement in pain reduction on operation day post-PRK (MD = -0.64; 95 % CI, -1.63 to 0.35; p-value = 0.20) or after 24 h of operation (MD = -0.45; 95 % CI, -2.01 to 1.11; p-value = 0.57). No significant benefit in terms of total rescue analgesia use post-PRK was observed (MD = -0.69; 95 % CI, -2.88 to 1.51; p-value = 0.5). However, a statistically significant benefit was observed two days after PRK (MD = -0.66 (95 % CI, -1.27 to -0.05; p-value = 0.03).</p></div><div><h3>Conclusion</h3><p>Gabapentinoids do not show significant efficacy in pain resolution post-PRK as compared to the placebo.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100039"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295025352400039X/pdfft?md5=9bbdfd1ad97cad791761a02d2e416e11&pid=1-s2.0-S295025352400039X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141415067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast cancer orbital metastases: Clinical, histopathological features and disease related survival in a retrospective case series 乳腺癌眼眶转移:回顾性病例系列中的临床、组织病理学特征和疾病相关生存率。
Pub Date : 2024-06-13 DOI: 10.1016/j.ajoint.2024.100040
Sofia Peschiaroli , Fabrizio Piccinni , Giovanni Cuffaro , Monica Maria Pagliara , Maria Grazia Sammarco , Antonio Mulè , Angela Santoro , Mariachiara Savino , Federico Giannuzzi , Tommaso Tartaglione , Gustavo Savino

Purpose

To analyze the clinical, radiological and histopathological features, and long-term follow-up of patients with orbital metastases originating from a primary breast carcinoma. Main outcomes were: demographic characteristics of the population, clinical ophthalmological presentation, histological features, orbital metastasis latency, disease related survival, mortality rate.

Design

A retrospective observational case-series.

Methods

The medical records of 10 female patients affected by orbital metastases originating from a primary breast carcinoma referring at our tertiary referral center from 01/2016 to 12/2023, were reviewed.

Results

The median age was 63 (71.50 - 57.25) years (time of orbital biopsy). The prevalent histotype of orbital metastases of breast cancer was lobular 9.00 (90 %). The median orbital metastasis latency time in months was 9 months (IQR: 11 - 5) (in one case the orbital metastases were the first manifestation of an unknown primary tumor). The median Disease Related Survival (DRS) during the observation period was 17.50 months and the 24 months survival rate 57.14 %. The overall Mortality Rate in our population was 60 %.

Conclusions

The most frequent histotype of breast cancer orbital metastasis is the lobular one. The primary tumor precedes the onset of orbital metastasis in the majority of cases and tends to present with the classic symptoms of a mass occupying and infiltrating space. Orbital metastases are a sign that the disease is at an advanced stage, the mortality rate is high and DRS low.

目的分析原发性乳腺癌眼眶转移患者的临床、放射学和组织病理学特征以及长期随访情况。结果中位年龄为63(71.50 - 57.25)岁(眼眶活检时间)。乳腺癌眼眶转移的常见组织类型为小叶型9.00(90%)。眼眶转移瘤潜伏时间的中位数为 9 个月(IQR:11 - 5)(其中一个病例的眼眶转移瘤是未知原发肿瘤的首次表现)。观察期间疾病相关生存期(DRS)的中位数为 17.50 个月,24 个月生存率为 57.14%。结论乳腺癌眼眶转移最常见的组织类型是小叶型。在大多数病例中,原发肿瘤在眼眶转移发生之前就已存在,而且往往表现为肿块占据和浸润空间的典型症状。眼眶转移是疾病进入晚期的标志,死亡率高,DRS 低。
{"title":"Breast cancer orbital metastases: Clinical, histopathological features and disease related survival in a retrospective case series","authors":"Sofia Peschiaroli ,&nbsp;Fabrizio Piccinni ,&nbsp;Giovanni Cuffaro ,&nbsp;Monica Maria Pagliara ,&nbsp;Maria Grazia Sammarco ,&nbsp;Antonio Mulè ,&nbsp;Angela Santoro ,&nbsp;Mariachiara Savino ,&nbsp;Federico Giannuzzi ,&nbsp;Tommaso Tartaglione ,&nbsp;Gustavo Savino","doi":"10.1016/j.ajoint.2024.100040","DOIUrl":"10.1016/j.ajoint.2024.100040","url":null,"abstract":"<div><h3>Purpose</h3><p>To analyze the clinical, radiological and histopathological features, and long-term follow-up of patients with orbital metastases originating from a primary breast carcinoma. Main outcomes were: demographic characteristics of the population, clinical ophthalmological presentation, histological features, orbital metastasis latency, disease related survival, mortality rate.</p></div><div><h3>Design</h3><p>A retrospective observational case-series.</p></div><div><h3>Methods</h3><p>The medical records of 10 female patients affected by orbital metastases originating from a primary breast carcinoma referring at our tertiary referral center from 01/2016 to 12/2023, were reviewed.</p></div><div><h3>Results</h3><p>The median age was 63 (71.50 - 57.25) years (time of orbital biopsy). The prevalent histotype of orbital metastases of breast cancer was lobular 9.00 (90 %). The median orbital metastasis latency time in months was 9 months (IQR: 11 - 5) (in one case the orbital metastases were the first manifestation of an unknown primary tumor). The median Disease Related Survival (DRS) during the observation period was 17.50 months and the 24 months survival rate 57.14 %. The overall Mortality Rate in our population was 60 %.</p></div><div><h3>Conclusions</h3><p>The most frequent histotype of breast cancer orbital metastasis is the lobular one. The primary tumor precedes the onset of orbital metastasis in the majority of cases and tends to present with the classic symptoms of a mass occupying and infiltrating space. Orbital metastases are a sign that the disease is at an advanced stage, the mortality rate is high and DRS low.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000406/pdfft?md5=708f717b6412a510ebd174d9031fd904&pid=1-s2.0-S2950253524000406-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141396748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features and associations of optic neuritis in the Middle East: A cross-sectional study 中东视神经炎的特征与关联:横断面研究
Pub Date : 2024-06-08 DOI: 10.1016/j.ajoint.2024.100038
Ayah Hajjar , Anu Jacob , Scott Smith , Luai Eldweik

Background

Differences exist in the clinical profile of optic neuritis (ON) among various populations. The present study outlines the features of optic neuritis and its associations in Middle Eastern population.

Methods

In a single tertiary care neuro-ophthalmology clinic, we reviewed charts between 2016 and 2021, to identify patients with optic neuritis. Patients with at least one single episode of ON, and a follow up for at least 6 months were only included. Patients from countries outside the Middle East were not eligible. We performed a sub-analysis using data from the clinic, laboratory, and radiological findings to classify patients with optic neuritis into 4 groups: idiopathic ON, multiple sclerosis associated optic neuritis (MS-ON), neuromyelitis optica spectrum disorder associated optic neuritis (NMOSD-ON), and myelin oligodendrocyte glycoprotein associated disease optic neuritis (MOGAD-ON).

Results

77 patients met the criteria for inclusion in the study. Approximately, two thirds of the patients (64%, 95% CI [0.52–0.74]) had MS-ON, 17 patients had idiopathic ON (22.6%, 95% CI [0.13–0.33]), 6 patients were diagnosed with NMOSD-ON (8%, 95% CI [0.02–0.16]), and 4 patients had MOG-ON (5.3%, 95% CI [0.01–0.13]). More than half of patients with idiopathic ON were found to have clinically isolated syndrome (CIS) and thus to be at high risk of developing MS. Among all patients enrolled in the study, the mean age was 29.8 ± 9.53 years. Patients with MS-ON and MOG-ON were relatively younger compared to patients from other groups (P = 0.0005). There was a female preponderance among all groups except MOG-ON, where 80% were males (P = 0.11). The pre- and post-treatment logMAR visual acuity (VA) tended to be worse in NMOSD-ON than other categories (P = 0.062). Optic disc swelling was more common among patients with MOGAD-ON, and least common in patients with NMOSD (100% vs 0%, P = 0.001). 5 patients presented with simultaneous bilateral involvement, and all but one had NMOSD-ON. 29% of patients had recurrence during the time of the study with significant difference in prevalence across groups. There was no difference in the involvement of the chiasm, or the retro-chiasmal pathways across groups.

Conclusions

Our study demonstrates that multiple sclerosis (MS) is the predominant CNS demyelinating disease associated with optic neuritis (ON) in the Middle Eastern population, mirroring trends observed in Western populations. The clinical and radiological features of each subtype showed no significant divergence compared to findings from studies conducted in other regions globally. These insights contribute to a deeper understanding of ON's clinical spectrum and aid in refining diagnostic and management strategies in the Middle Eastern population.

背景不同人群的视神经炎(ON)临床特征存在差异。本研究概述了中东人群视神经炎的特征及其相关性。方法在一家三级护理神经眼科诊所,我们查阅了 2016 年至 2021 年间的病历,以确定视神经炎患者。仅纳入至少单次发病、随访至少 6 个月的视神经炎患者。来自中东以外国家的患者不符合条件。我们利用临床、实验室和放射学检查结果的数据进行了子分析,将视神经炎患者分为 4 组:特发性视神经炎、多发性硬化症相关性视神经炎(MS-ON)、神经脊髓炎视谱系障碍相关性视神经炎(NMOSD-ON)和髓鞘少突胶质细胞糖蛋白相关疾病视神经炎(MOGAD-ON)。约三分之二的患者(64%,95% CI [0.52-0.74])患有 MS-ON,17 名患者患有特发性 ON(22.6%,95% CI [0.13-0.33]),6 名患者被诊断为 NMOSD-ON(8%,95% CI [0.02-0.16]),4 名患者患有 MOG-ON(5.3%,95% CI [0.01-0.13])。一半以上的特发性ON患者被发现患有临床孤立综合征(CIS),因此是多发性硬化症的高危人群。在所有参与研究的患者中,平均年龄为(29.8 ± 9.53)岁。与其他组别患者相比,MS-ON 和 MOG-ON 患者相对年轻(P = 0.0005)。除MOG-ON患者80%为男性外,其他各组患者均以女性居多(P = 0.11)。NMOSD-ON患者治疗前和治疗后的logMAR视力(VA)往往差于其他组别(P = 0.062)。视盘肿胀在 MOGAD-ON 患者中更为常见,而在 NMOSD 患者中最少见(100% vs 0%,P = 0.001)。5名患者同时出现双侧受累,除一人外,其余均为NMOSD-ON。29%的患者在研究期间复发,各组患病率差异显著。结论我们的研究表明,多发性硬化症(MS)是中东人群中与视神经炎(ON)相关的主要中枢神经系统脱髓鞘疾病,这与西方人群中观察到的趋势一致。与全球其他地区的研究结果相比,每个亚型的临床和放射学特征均无明显差异。这些见解有助于加深对ON临床范围的理解,并有助于完善中东人群的诊断和管理策略。
{"title":"Features and associations of optic neuritis in the Middle East: A cross-sectional study","authors":"Ayah Hajjar ,&nbsp;Anu Jacob ,&nbsp;Scott Smith ,&nbsp;Luai Eldweik","doi":"10.1016/j.ajoint.2024.100038","DOIUrl":"10.1016/j.ajoint.2024.100038","url":null,"abstract":"<div><h3>Background</h3><p>Differences exist in the clinical profile of optic neuritis (ON) among various populations. The present study outlines the features of optic neuritis and its associations in Middle Eastern population.</p></div><div><h3>Methods</h3><p>In a single tertiary care neuro-ophthalmology clinic, we reviewed charts between 2016 and 2021, to identify patients with optic neuritis. Patients with at least one single episode of ON, and a follow up for at least 6 months were only included. Patients from countries outside the Middle East were not eligible. We performed a sub-analysis using data from the clinic, laboratory, and radiological findings to classify patients with optic neuritis into 4 groups: idiopathic ON, multiple sclerosis associated optic neuritis (MS-ON), neuromyelitis optica spectrum disorder associated optic neuritis (NMOSD-ON), and myelin oligodendrocyte glycoprotein associated disease optic neuritis (MOGAD-ON).</p></div><div><h3>Results</h3><p>77 patients met the criteria for inclusion in the study. Approximately, two thirds of the patients (64%, 95% CI [0.52–0.74]) had MS-ON, 17 patients had idiopathic ON (22.6%, 95% CI [0.13–0.33]), 6 patients were diagnosed with NMOSD-ON (8%, 95% CI [0.02–0.16]), and 4 patients had MOG-ON (5.3%, 95% CI [0.01–0.13]). More than half of patients with idiopathic ON were found to have clinically isolated syndrome (CIS) and thus to be at high risk of developing MS. Among all patients enrolled in the study, the mean age was 29.8 ± 9.53 years. Patients with MS-ON and MOG-ON were relatively younger compared to patients from other groups (<em>P</em> = 0.0005). There was a female preponderance among all groups except MOG-ON, where 80% were males (<em>P</em> = 0.11). The pre- and post-treatment logMAR visual acuity (VA) tended to be worse in NMOSD-ON than other categories (<em>P</em> = 0.062). Optic disc swelling was more common among patients with MOGAD-ON, and least common in patients with NMOSD (100% vs 0%, <em>P</em> = 0.001). 5 patients presented with simultaneous bilateral involvement, and all but one had NMOSD-ON. 29% of patients had recurrence during the time of the study with significant difference in prevalence across groups. There was no difference in the involvement of the chiasm, or the retro-chiasmal pathways across groups.</p></div><div><h3>Conclusions</h3><p>Our study demonstrates that multiple sclerosis (MS) is the predominant CNS demyelinating disease associated with optic neuritis (ON) in the Middle Eastern population, mirroring trends observed in Western populations. The clinical and radiological features of each subtype showed no significant divergence compared to findings from studies conducted in other regions globally. These insights contribute to a deeper understanding of ON's clinical spectrum and aid in refining diagnostic and management strategies in the Middle Eastern population.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000388/pdfft?md5=666d6d5ec2ff123419d5341626d71eaa&pid=1-s2.0-S2950253524000388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141402548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of facedown and non-facedown positions after vitrectomy with fovea-sparing internal limiting membrane peeling and air tamponade for treating myopic foveoschisis with foveal detachment: A prospective, randomized interventional study 前瞻性随机干预研究:玻璃体切割术后面朝下体位和非面朝下体位与保留眼窝内缘膜剥离术和空气填塞术治疗近视性眼底病伴眼窝脱离的比较
Pub Date : 2024-06-02 DOI: 10.1016/j.ajoint.2024.100036
Ke Zhu , Boya Lei , Fang Song , Rui Jiang , Qing Chang , Gezhi Xu

Purpose

To compare the anatomical and visual outcomes after vitrectomy with facedown (FD) or non-FD positions for treating myopic foveoschisis (MF) with foveal detachment.

Design

Prospective, randomized interventional study.

Methods

55 eyes with MF and foveal detachment that underwent vitrectomy with fovea-sparing internal limiting membrane (ILM) peeling and air tamponade were randomized to either the postoperative FD (26 eyes) or non-FD (29 eyes) positions. Best-corrected visual acuity (BCVA) and optical coherence tomography were assessed at baseline, 2 weeks, 3 months, and 6 months after vitrectomy with fovea-sparing ILM peeling and air tamponade with the FD or non-FD positions. Logistic and linear regression analyses were performed to study correlations between clinical factors and foveoschisis resolution and postoperative BCVA.

Results

All patients completed ≥6 months of follow-up. MF and foveal detachment were completely resolved in 22 eyes (92 %) in the FD group and 22 eyes (76 %) in the non-FD group (P = 0.160). Macular hole-associated retinal detachment occurred in one eye in the FD (4 %) and non-FD (3 %) groups. The postoperative best-corrected visual acuity (BCVA) at 6 months did not differ significantly between the two groups (P = 0.495). The BCVA improved by ≥0.3 logMAR in 14 eyes (58 %) in the FD group versus 17 eyes (59 %) in the non-FD group (P = 0.983). Central foveal thickness (CFT) and height of foveal detachment were significantly associated with foveoschisis resolution (P = 0.045 and 0.039, respectively). Better preoperative BCVA and foveoschisis resolution were significantly associated with better postoperative BCVA (P = 0.031 and 0.003, respectively).

Conclusions

The non-FD position appeared to be as effective as the FD position after vitrectomy with fovea-sparing ILM peeling and air tamponade for treating MF with foveal detachment.

目的比较采用面朝下(FD)或非FD体位进行玻璃体切除术治疗近视性眼窝裂孔(MF)伴眼窝脱离后的解剖学和视觉结果。方法55只眼患MF伴眼窝脱离并接受了玻璃体切除术,同时进行了保留眼窝的内层限界膜(ILM)剥离和空气填塞,这些眼被随机分配到术后FD体位(26只眼)或非FD体位(29只眼)。最佳矫正视力(BCVA)和光学相干断层扫描分别在玻璃体切割术后基线、2周、3个月和6个月进行了评估,并采用FD或非FD体位进行了保留眼窝的ILM剥离和空气填塞。对临床因素与眼窝裂解和术后BCVA之间的相关性进行了逻辑和线性回归分析。在 FD 组和非 FD 组中,分别有 22 只眼睛(92%)和 22 只眼睛(76%)的 MF 和眼窝脱离完全消除(P = 0.160)。在 FD 组(4%)和非 FD 组(3%)中,有一只眼睛发生了黄斑孔相关性视网膜脱离。两组患者术后 6 个月的最佳矫正视力(BCVA)无显著差异(P = 0.495)。FD组有14只眼睛(58%)的BCVA提高了≥0.3 logMAR,而非FD组有17只眼睛(59%)的BCVA提高了≥0.3 logMAR(P = 0.983)。中心眼窝厚度(CFT)和眼窝脱离高度与眼窝裂解显著相关(P = 0.045 和 0.039)。结论在进行玻璃体切除术,同时进行疏通眼窝的ILM剥离和气囊填塞术治疗伴有眼窝脱离的MF时,非FD体位似乎与FD体位一样有效。
{"title":"Comparison of facedown and non-facedown positions after vitrectomy with fovea-sparing internal limiting membrane peeling and air tamponade for treating myopic foveoschisis with foveal detachment: A prospective, randomized interventional study","authors":"Ke Zhu ,&nbsp;Boya Lei ,&nbsp;Fang Song ,&nbsp;Rui Jiang ,&nbsp;Qing Chang ,&nbsp;Gezhi Xu","doi":"10.1016/j.ajoint.2024.100036","DOIUrl":"10.1016/j.ajoint.2024.100036","url":null,"abstract":"<div><h3>Purpose</h3><p>To compare the anatomical and visual outcomes after vitrectomy with facedown (FD) or non-FD positions for treating myopic foveoschisis (MF) with foveal detachment.</p></div><div><h3>Design</h3><p>Prospective, randomized interventional study.</p></div><div><h3>Methods</h3><p>55 eyes with MF and foveal detachment that underwent vitrectomy with fovea-sparing internal limiting membrane (ILM) peeling and air tamponade were randomized to either the postoperative FD (26 eyes) or non-FD (29 eyes) positions. Best-corrected visual acuity (BCVA) and optical coherence tomography were assessed at baseline, 2 weeks, 3 months, and 6 months after vitrectomy with fovea-sparing ILM peeling and air tamponade with the FD or non-FD positions. Logistic and linear regression analyses were performed to study correlations between clinical factors and foveoschisis resolution and postoperative BCVA.</p></div><div><h3>Results</h3><p>All patients completed ≥6 months of follow-up. MF and foveal detachment were completely resolved in 22 eyes (92 %) in the FD group and 22 eyes (76 %) in the non-FD group (<em>P</em> = 0.160). Macular hole-associated retinal detachment occurred in one eye in the FD (4 %) and non-FD (3 %) groups. The postoperative best-corrected visual acuity (BCVA) at 6 months did not differ significantly between the two groups (<em>P</em> = 0.495). The BCVA improved by ≥0.3 logMAR in 14 eyes (58 %) in the FD group versus 17 eyes (59 %) in the non-FD group (<em>P</em> = 0.983). Central foveal thickness (CFT) and height of foveal detachment were significantly associated with foveoschisis resolution (<em>P</em> = 0.045 and 0.039, respectively). Better preoperative BCVA and foveoschisis resolution were significantly associated with better postoperative BCVA (<em>P</em> = 0.031 and 0.003, respectively).</p></div><div><h3>Conclusions</h3><p>The non-FD position appeared to be as effective as the FD position after vitrectomy with fovea-sparing ILM peeling and air tamponade for treating MF with foveal detachment.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000364/pdfft?md5=4287fdd4dd68809ab1887f43c8b1a98d&pid=1-s2.0-S2950253524000364-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141280932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the impact of tadalafil on progression of age-related macular degeneration: a health insurance claims database analysis 调查他达拉非对老年性黄斑变性进展的影响:医疗保险索赔数据库分析
Pub Date : 2024-06-01 DOI: 10.1016/j.ajoint.2024.100037
Tracy Z. Lang , John R. O'Fee , Khristina I. Lung , David S. Boyer , Andrew A. Moshfeghi , Brian C. Toy

Purpose

To assess the effect of tadalafil use on progression of early/intermediate to advanced exudative or non-exudative age-related macular degeneration (AMD) in a real-world population.

Design

Retrospective cohort study utilizing Optum's de-identified Clinformatics® Data Mart Database (CDM).

Methods

Patients were included from January 2015 to December 2020 aged 55 and older with an index International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of early or intermediate AMD who had a 2-year period of continuous enrollment prior to the index diagnosis date (lookback period), 5 years of continuous follow-up, and who did not meet any exclusion criteria (claims for a phosphodiesterase-5 (PDE-5) inhibitor other than tadalafil during the study, diagnosis of advanced non-exudative or exudative AMD, or claims for exudative AMD treatment during the lookback period). Treated patients with claims for tadalafil during the study period were matched 1:1 to untreated controls by age, sex, race, and smoking status. We assessed the effect of any tadalafil use, high (≥2700 mg) cumulative dose tadalafil vs. matched untreated controls, high (>2700 mg) vs. low (≤2700 mg) cumulative dose tadalafil, and the 2-year cumulative dose of tadalafil (per 100 mg) as a continuous variable on incidence of progression to exudative or advanced non-exudative AMD during the 2-year follow-up.

Results

There was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD in the control vs treated groups (OR = 0.802, 95% CI (0.558–1.152), p = 0.233; OR = 1.326, 95% CI (0.757–2.323), p = 0.323). High (≥2700 mg) cumulative dose tadalafil was not associated with a significant difference in odds of progression to exudative AMD or advanced non-exudative AMD when compared to the matched controls (OR = 0.455, 95% CI (0.202–1.025), p = 0.057; OR = 1.000, 95% CI (0.318–3.142), p = 1.000). There was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD in the high (>2700 mg) vs. low (≤2700 mg) cumulative dose tadalafil (OR = 0.590, 95% CI (0.296–1.177), p = 0.134; OR = 1.039, 95% CI (0.440–2.460), p = 0.931). Lastly, there was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD when assessing the 2-year cumulative tadalafil dose (per 100 mg) as a continuous variable (OR = 1.000, 95% CI (1.000–1.000), p = 0.305; OR = 1.000, 95% CI (1.000–1.000), p = 0.878).

Conclusion

In a retrospective cohort study of a large nationwide health insurance claims database, tadalafil use was not associated with progression of AMD.

目的评估在现实世界人群中使用他达拉非对早期/中期渗出性或非渗出性老年性黄斑变性(AMD)进展的影响。方法纳入 2015 年 1 月至 2020 年 12 月期间 55 岁及以上、国际疾病分类第十次修订版(ICD-10)诊断为早期或中期 AMD 的患者,这些患者在诊断日期(回溯期)之前有 2 年的连续注册期、连续随访 5 年,且不符合任何排除标准(在研究期间申请使用除他达拉非以外的磷酸二酯酶-5 (PDE-5) 抑制剂、诊断为晚期非渗出性或渗出性 AMD 或在回溯期内申请渗出性 AMD 治疗)。在研究期间报销了他达拉非的治疗患者与未治疗的对照组按年龄、性别、种族和吸烟状况进行了 1:1 的配对。我们评估了使用任何他达拉非、高剂量(≥2700 毫克)他达拉非累积剂量与匹配的未治疗对照组、高剂量(>2700 毫克)与低剂量(≤2700 毫克)他达拉非累积剂量以及他达拉非 2 年累积剂量(每 100 毫克)作为连续变量对 2 年随访期间进展为渗出性或晚期非渗出性 AMD 的发生率的影响。结果对照组与治疗组发展为渗出性AMD或晚期非渗出性AMD的几率无明显差异(OR = 0.802,95% CI (0.558-1.152),p = 0.233;OR = 1.326,95% CI (0.757-2.323),p = 0.323)。与匹配对照组相比,高累积剂量(≥2700 毫克)他达拉非与进展为渗出性老年黄斑病变或晚期非渗出性老年黄斑病变的几率无显著差异(OR = 0.455,95% CI (0.202-1.025),p = 0.057;OR = 1.000,95% CI (0.318-3.142),p = 1.000)。高累积剂量(>2700 毫克)与低累积剂量(≤2700 毫克)他达拉非相比,进展为渗出性老年黄斑病变或晚期非渗出性老年黄斑病变的几率没有明显差异(OR = 0.590,95% CI (0.296-1.177),p = 0.134;OR = 1.039,95% CI (0.440-2.460),p = 0.931)。最后,将 2 年的他达拉非累积剂量(每 100 毫克)作为连续变量进行评估时,进展为渗出性 AMD 或晚期非渗出性 AMD 的几率没有明显差异(OR = 1.000,95% CI (1.000-1.000),p = 0.134)。结论在一项大型全国性健康保险索赔数据库的回顾性队列研究中,他达拉非的使用与AMD的进展无关。
{"title":"Investigating the impact of tadalafil on progression of age-related macular degeneration: a health insurance claims database analysis","authors":"Tracy Z. Lang ,&nbsp;John R. O'Fee ,&nbsp;Khristina I. Lung ,&nbsp;David S. Boyer ,&nbsp;Andrew A. Moshfeghi ,&nbsp;Brian C. Toy","doi":"10.1016/j.ajoint.2024.100037","DOIUrl":"10.1016/j.ajoint.2024.100037","url":null,"abstract":"<div><h3>Purpose</h3><p>To assess the effect of tadalafil use on progression of early/intermediate to advanced exudative or non-exudative age-related macular degeneration (AMD) in a real-world population.</p></div><div><h3>Design</h3><p>Retrospective cohort study utilizing Optum's de-identified Clinformatics® Data Mart Database (CDM).</p></div><div><h3>Methods</h3><p>Patients were included from January 2015 to December 2020 aged 55 and older with an index International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of early or intermediate AMD who had a 2-year period of continuous enrollment prior to the index diagnosis date (lookback period), 5 years of continuous follow-up, and who did not meet any exclusion criteria (claims for a phosphodiesterase-5 (PDE-5) inhibitor other than tadalafil during the study, diagnosis of advanced non-exudative or exudative AMD, or claims for exudative AMD treatment during the lookback period). Treated patients with claims for tadalafil during the study period were matched 1:1 to untreated controls by age, sex, race, and smoking status. We assessed the effect of any tadalafil use, high (≥2700 mg) cumulative dose tadalafil vs. matched untreated controls, high (&gt;2700 mg) vs. low (≤2700 mg) cumulative dose tadalafil, and the 2-year cumulative dose of tadalafil (per 100 mg) as a continuous variable on incidence of progression to exudative or advanced non-exudative AMD during the 2-year follow-up.</p></div><div><h3>Results</h3><p>There was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD in the control vs treated groups (OR = 0.802, 95% CI (0.558–1.152), <em>p</em> = 0.233; OR = 1.326, 95% CI (0.757–2.323), <em>p</em> = 0.323). High (≥2700 mg) cumulative dose tadalafil was not associated with a significant difference in odds of progression to exudative AMD or advanced non-exudative AMD when compared to the matched controls (OR = 0.455, 95% CI (0.202–1.025), <em>p</em> = 0.057; OR = 1.000, 95% CI (0.318–3.142), <em>p</em> = 1.000). There was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD in the high (&gt;2700 mg) vs. low (≤2700 mg) cumulative dose tadalafil (OR = 0.590, 95% CI (0.296–1.177), <em>p</em> = 0.134; OR = 1.039, 95% CI (0.440–2.460), <em>p</em> = 0.931). Lastly, there was no significant difference in odds of progression to exudative AMD or advanced non-exudative AMD when assessing the 2-year cumulative tadalafil dose (per 100 mg) as a continuous variable (OR = 1.000, 95% CI (1.000–1.000), <em>p</em> = 0.305; OR = 1.000, 95% CI (1.000–1.000), <em>p</em> = 0.878).</p></div><div><h3>Conclusion</h3><p>In a retrospective cohort study of a large nationwide health insurance claims database, tadalafil use was not associated with progression of AMD.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000376/pdfft?md5=7877785fb274c73ead16d562c34f658d&pid=1-s2.0-S2950253524000376-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141274978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
AJO International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1